Abeona Therapeutics (ABEO) Other Non-Current Liabilities (2012 - 2026)

Abeona Therapeutics' Other Non-Current Liabilities history runs 14 years deep, the most recent figure standing at $13.5 million for Q1 2026.

• In Q1 2026, Other Non-Current Liabilities fell 45.43% year-over-year to $13.5 million; the TTM figure through Mar 2026 stood at $13.5 million (down 45.43% YoY), while the FY2025 annual figure was $18.9 million, down 40.96% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $13.5 million, down from $18.9 million in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $48.7 million in Q1 2024, with the low at $200000.0 in Q1 2022.
• The 5-year median for Other Non-Current Liabilities is $22.6 million (2025), against an average of $19.9 million.
• The sharpest annual moves came in 2023 and 2024: Other Non-Current Liabilities surged 13461.0% in 2023, then plunged 95.94% in 2024.
• Abeona Therapeutics' Other Non-Current Liabilities stood at $19.7 million in 2022, then surged by 59.5% to $31.4 million in 2023, then gained by 2.11% to $32.0 million in 2024, then sank by 40.96% to $18.9 million in 2025, then decreased by 28.49% to $13.5 million in 2026.
• Business Quant data shows ABEO's Other Non-Current Liabilities at $13.5 million in Q1 2026, $18.9 million in Q4 2025, and $22.6 million in Q3 2025.